869335-19-3

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[[2-(triMethylsilyl)ethoxy]Methyl]-
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[[2-(triMethylsilyl)ethoxy]Methyl]-;4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine
• CAS NO: 869335-19-3
• Molecular Formula: C₁₃H₁₉ClN₂OSi
• Molecular Weight: 282.84126
• Mol File: 869335-19-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[[2-(triMethylsilyl)ethoxy]Methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[[2-(triMethylsilyl)ethoxy]Methyl]-(869335-19-3)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine, 4-chloro-1-[[2-(triMethylsilyl)ethoxy]Methyl]-(869335-19-3)

Safety Data

• Hazardous Substances Data: 869335-19-3(Hazardous Substances Data)

Usage

Core structure

pyrrolopyridine

Substitution

4-chloro

Alkyl group

1-[[2-(trimethylsilyl)ethoxy]methyl]

Usage

synthesis of pharmaceutical agents and organic compounds

Reactivity

useful for cross-coupling reactions

Building block

for the development of potential drug candidates

Heterocyclic structure

provides opportunities for bioactivity and further functionalization

Value

valuable chemical building block in medicinal and organic chemistry

Upstream product

• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 55052-28-3 4-chloro-7-azaindole 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 271-63-6 7-Azaindole 
• 1221714-47-1 4-chloro-2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE

The present invention relates to a pyrrolopyridine derivative and a pharmaceutical composition comprising the same as an active ingredient for prevention or treatment of a protein kinase-related disease. The pyrrolopyridine derivative has excellent inhibitory activity against various protein kinases including LRRK2, DYRK1, and CLK1 and exhibits an excellent suppressive effect on the growth of triple-negative breast cancer cells. A pharmaceutical composition comprising the same as an active ingredient can be advantageously used for treating or preventing protein kinase-related diseases, inter alia, cancers, degenerative brain diseases, and inflammatory diseases, and specifically for treating triple-negative breast cancer.

Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping

The high genomic instability of non-small cell lung cancer tumors leads to the rapid development of resistance against promising EGFR tyrosine kinase inhibitors (TKIs). A recently detected triple mutation compromises the activity of the gold standard third-generation EGFR inhibitors. We have prepared a set of trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif as a new structural class of EGFR inhibitors by a target hopping approach from p38α MAPK inhibitor templates. On the basis of an iterative approach of docking, compound preparation, biological testing, and SAR interpretation, robust and flexible synthetic routes were established. As a result, we report two reversible inhibitors 11d and 11e of the clinically challenging triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range. Furthermore, we developed a kinome selective irreversible inhibitor 45a with an IC50 value of 1 nM against the EGFR L858R/T790M double mutant. Target binding kinetics and metabolic stability data are included. These potent mutant EGFR inhibitors may serve as a basis for the development of structurally novel EGFR probes, tools, or candidates.

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.